Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : Alny save search
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda drug review treatment application
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
onpattro treatment drug application food
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.43%
H: 3.16%
C: 2.44%
onpattro treatment drug application food
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.2%
H: 0.26%
C: -3.28%
drug application review
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.65%
H: 3.47%
C: 2.28%
oxlumo new drug treatment application drug food
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
oxlumo treatment europe application expansion drug food
Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI for the Treatment of Acute Hepatic Porphyria (AHP) in Adults
Published: 2021-10-18 (Crawled : 18:00) - biospace.com/
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -2.37%
treatment positive drug technology hepatitis
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | News | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.01%
H: 1.3%
C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
Published: 2021-06-24 (Crawled : 12:00) - biospace.com/
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.96%
H: 0.37%
C: -1.49%
new drug food treatment drug
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
NVO | News | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -1.58%
H: 0.7%
C: -0.32%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.57%
H: 1.91%
C: 0.46%
new drug fda fda acceptance drug application
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.